Compared to Estimates, Exelixis (EXEL) Q4 Earnings: A Look at Key Metrics

Core Insights - Exelixis reported $598.66 million in revenue for Q4 2025, a 5.6% year-over-year increase, with an EPS of $0.94 compared to $0.55 a year ago, exceeding both revenue and EPS estimates [1][4] Revenue Performance - Net product revenues reached $546.58 million, surpassing the average estimate of $529.04 million by nine analysts, reflecting a 6.1% increase year-over-year [4] - Collaboration revenues were reported at $52.09 million, exceeding the average estimate of $49.91 million, marking a significant year-over-year increase of 2289.3% [4] - CABOMETYX generated $544.7 million in net product revenues, slightly below the average estimate of $554.08 million, but still showing a 6.2% year-over-year growth [4] - COMETRIQ reported net product revenues of $1.8 million, which fell short of the average estimate of $3.15 million, indicating a year-over-year decline of 25.6% [4] - License revenues from collaboration reached $66.36 million, exceeding the average estimate of $48.87 million from five analysts [4] Stock Performance - Exelixis shares have returned -0.3% over the past month, while the Zacks S&P 500 composite remained unchanged [3] - The stock holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [3]